Morning vs. afternoon chemo: which is better for lung cancer?

NCT ID NCT05549037

Completed Disease control Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving immunochemotherapy in the morning or afternoon affects how long people with advanced non-small cell lung cancer live without their disease getting worse. 210 patients were randomly assigned to receive treatment before or after 3 PM. The goal is to see if timing can improve treatment effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab, Sintilimab (immunochemotherapy given at different times of day)
What this could lead to: If timing matters, this could lead to a simple way to improve how well standard lung cancer treatments work without adding new drugs.
What could go wrong: This is a completed phase 3 trial, but the effect of timing may be small or not apply to all patients. Results are not yet widely confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.